Matthew Caufield
Stock Analyst at HC Wainwright & Co.
(4.61)
# 191
Out of 5,072 analysts
124
Total ratings
55.08%
Success rate
29.57%
Average return
Main Sectors:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $30 → $5 | $4.16 | +20.19% | 8 | Nov 17, 2025 | |
| KOD Kodiak Sciences | Maintains: Buy | $24 → $26 | $22.44 | +15.86% | 7 | Nov 17, 2025 | |
| IMUX Immunic | Maintains: Buy | $10 → $8 | $0.70 | +1,041.23% | 6 | Nov 14, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $52 → $56 | $43.36 | +29.15% | 13 | Nov 12, 2025 | |
| FBLG FibroBiologics | Maintains: Buy | $10 → $5 | $0.27 | +1,737.56% | 7 | Nov 5, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $20 → $26 | $15.17 | +71.39% | 11 | Oct 31, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $8 → $6 | $1.59 | +277.36% | 2 | Oct 30, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Buy | $30 → $44 | $40.53 | +8.56% | 5 | Oct 28, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $72 → $88 | $80.50 | +9.32% | 2 | Oct 20, 2025 | |
| DMAC DiaMedica Therapeutics | Reiterates: Buy | $12 | $9.12 | +31.58% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $16 | $3.50 | +357.14% | 9 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $56 | $30.72 | +82.29% | 7 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.02 | +296.04% | 4 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $10 | $5.93 | +68.63% | 1 | Jun 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $5.59 | +78.89% | 13 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $16.45 | +94.59% | 3 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $10.99 | +227.57% | 18 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $28 | $449.06 | -93.76% | 1 | Aug 22, 2023 |
Adverum Biotechnologies
Nov 17, 2025
Downgrades: Neutral
Price Target: $30 → $5
Current: $4.16
Upside: +20.19%
Kodiak Sciences
Nov 17, 2025
Maintains: Buy
Price Target: $24 → $26
Current: $22.44
Upside: +15.86%
Immunic
Nov 14, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $0.70
Upside: +1,041.23%
Mineralys Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $52 → $56
Current: $43.36
Upside: +29.15%
FibroBiologics
Nov 5, 2025
Maintains: Buy
Price Target: $10 → $5
Current: $0.27
Upside: +1,737.56%
Phathom Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $20 → $26
Current: $15.17
Upside: +71.39%
Akebia Therapeutics
Oct 30, 2025
Maintains: Buy
Price Target: $8 → $6
Current: $1.59
Upside: +277.36%
Zenas BioPharma
Oct 28, 2025
Maintains: Buy
Price Target: $30 → $44
Current: $40.53
Upside: +8.56%
Tarsus Pharmaceuticals
Oct 20, 2025
Maintains: Buy
Price Target: $72 → $88
Current: $80.50
Upside: +9.32%
DiaMedica Therapeutics
Aug 15, 2025
Reiterates: Buy
Price Target: $12
Current: $9.12
Upside: +31.58%
Aug 14, 2025
Reiterates: Neutral
Price Target: $16
Current: $3.50
Upside: +357.14%
Aug 1, 2025
Maintains: Buy
Price Target: $48 → $56
Current: $30.72
Upside: +82.29%
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $2.02
Upside: +296.04%
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $5.93
Upside: +68.63%
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.59
Upside: +78.89%
May 12, 2025
Reiterates: Buy
Price Target: $32
Current: $16.45
Upside: +94.59%
Mar 3, 2025
Reiterates: Buy
Price Target: $36
Current: $10.99
Upside: +227.57%
Aug 22, 2023
Reiterates: Buy
Price Target: $28
Current: $449.06
Upside: -93.76%